Note 10. Share-based Compensation:

During the nine months ended March 31, 2021 and 2020, the Company granted 0.7 million and 0.8 million stock options at weighted average grant prices of $269.64 and $190.80 and weighted average fair values of $57.50 and $37.01, respectively. During the nine months ended March 31, 2021 and 2020, the Company granted 23,367 and 30,858 restricted stock units at a weighted average fair value of $269.87 and $192.08, respectively. During the nine months ended March 31, 2021 and 2020, the Company granted 11,803 and 15,398 shares of restricted common stock shares at a weighted average fair value of $264.73 and $193.48.

Stock options for 505,137 and 398,320 shares of common stock with total intrinsic values of $108.0 million and $48.6 million were exercised during the nine months ended March 31, 2021 and 2020, respectively.

Stock-based compensation expense, inclusive of employer payroll tax, of $11.1 million and $7.6 million was included in selling, general and administrative expenses for the quarter ended March 31, 2021 and 2020, respectively. Stock-based compensation expense, inclusive of employer payroll tax, of $36.0 million and $26.1 million was included in selling, general, and administrative expenses for the nine months ended March 31, 2021 and 2020, respectively. Additionally, the company recognized $0.4 million and $1.5 million in cost of goods sold in the quarter and nine months ended March 31, 2021 respectively. As of March 31, 2021, there was $35.4 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.0 years.